Welcome to another episode of the Oncology Brothers! In this episode, we dived into the recent FDA approval of camizestrant for the treatment of hormone receptor–positive metastatic breast cancer, based on the SERENA-6 trial.

We welcomed Dr. Erica Mayer, a breast medical oncologist from the Dana-Farber Cancer Institute, who shared her insights on the trial's design, findings, and the significance of detecting ESR1 mutations before clinical progression. We discussed the implications of this approval, including the shift in treatment strategies, the importance of ctDNA monitoring, and the potential benefits for patient quality of life.

Key topics covered in this episode:

Overview of the SERENA-6 trial and its findings
The role of ESR1 mutations in treatment resistance
The efficacy and safety profile of camizestrant
Practical insights on integrating next-generation sequencing (NGS) testing into clinical practice
Management of side effects, including bradycardia and QT prolongation

Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information.

Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

⁠X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#Camizestrant, #SERENA6, #ESR1mutation, #BreastCancer, #OncologyBrothers

Camizestrant + CDK 46i FDA Approval in Hormone Receptor Positive Breast Cancer SERENA-6

Oncology Brothers: Practice-Changing Cancer Discussions

Camizestrant + CDK 46i FDA Approval in Hormone Receptor Positive Breast Cancer SERENA-6